First Tracks Biotherapeutics (TRAX) SEC Filings

First Tracks Biotherapeutics, Inc. (TRAX) registered up to 6,106,870 common shares for resale by selling stockholders. The shares were issued in a private placement that closed October 19, 2026, at $32.75 per share, generating approximately $200 million in gross proceeds for the company before placement agent fees and other offering expenses. TRAX will receive no proceeds from resales. The shares may not be sold until the registration statement is effective; holders may sell at prevailing market prices or in privately negotiated transactions.

TRAX is a clinical-stage biotechnology company developing antibody therapies for autoimmune and inflammatory diseases. Its pipeline includes ANB033, rosnilimab and ANB101. The company reported a net loss of $83.9 million for the six months ended June 30, 2026, compared with $89.6 million for the same period in 2025, and said existing cash, cash equivalents and investments are expected to fund its current operating plan beyond the next 12 months. The company reported positive Phase 2b rosnilimab data in rheumatoid arthritis, while Phase 2 data in ulcerative colitis was not positive.

First Tracks Biotherapeutics, Inc. (TRAX) closed a private placement of an aggregate 6,106,870 shares of common stock on October 19, 2026. At closing, it entered a registration rights agreement requiring it to file or confidentially submit a resale registration statement covering the investors’ shares as promptly as reasonably practicable, and no later than 30 days following the closing date.

First Tracks Biotherapeutics, Inc. agreed to issue and sell 6,106,870 common shares to a limited group of institutional investors in a private placement at $32.75 per share. The company expects approximately $200 million in gross proceeds before placement agent fees and other offering expenses. The securities will be unregistered and issued in reliance on an exemption from Securities Act registration requirements.

The placement is expected to close on October 19, 2026, subject to customary closing conditions. First Tracks Biotherapeutics intends to use the proceeds for general corporate purposes, including clinical development of ANB033, a CD122 antagonist. At closing, the company will enter into a registration rights agreement requiring it to file or confidentially submit a resale registration statement as promptly as reasonably practicable and no later than 30 days following closing. The company had 35,909,814 common shares issued and outstanding as of October 12, 2026. Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities are acting as placement agents.

First Tracks Biotherapeutics, Inc. (TRAX) reported positive top-line results from Cohort 1 of its Phase 1b ANB033 celiac disease trial. The 32 patients who completed dosing and a 14-day gluten challenge included 17 receiving ANB033 and 15 placebo. At Week 6, the least-squares mean change in villus-height-to-crypt-depth ratio was -0.17 with ANB033 and -0.66 with placebo, a +0.49 placebo-adjusted delta (p=0.009). Intraepithelial lymphocyte density changed -1.20 versus +18.83, a -20.03 placebo-adjusted delta (p<0.001).

During the challenge, symptoms did not increase in the ANB033 group; total symptom score differences were statistically significant from days 1–7, and moderate-to-severe symptom differences through days 1–12. The safety analysis covered 34 participants: no serious adverse events occurred; any adverse event was reported in 16 of 18 ANB033 participants (88.9%) and 16 of 16 placebo participants (100%). First Tracks anticipates Cohort 2 celiac top-line data in Q1 2027 and ANB033 eosinophilic esophagitis data in Q3 2027; it anticipates starting a late-stage celiac trial in 2027.

First Tracks Biotherapeutics, Inc. (TRAX) director John A. Orwin reported the settlement of 1,300 Restricted Stock Units into 1,300 shares of Common Stock on September 15, 2026, for no cash consideration. After this derivative exercise/conversion, he directly holds 17,995 shares of Common Stock. The RSU award vests in three equal installments on September 15, 2024, 2025 and 2026, subject to continued service.

First Tracks Biotherapeutics, Inc. (TRAX) director Ware J. Anthony exercised stock options to acquire 39,265 shares of common stock at an exercise price of $5.74 per share on September 2, 2026, then sold the same 39,265 shares at a weighted average price of $44.7764 per share, with individual sale prices ranging from $44.62 to $45.28. The stock options exercised were fully vested, and no Rule 10b5-1 trading plan is reported for these transactions. In addition, he continues to hold options to purchase up to 99,320 shares of common stock and 6,500 restricted stock units.

First Tracks Biotherapeutics, Inc. (TRAX) received a notice under Rule 144 that director Joe Anthony Ware plans to sell common stock. The planned sale covers 39,265 shares of common stock, expected to be effected through Morgan Stanley Smith Barney LLC Executive Financial Services on or after September 2, 2026.

The shares are to be issued from a stock option exercise with the issuer as the counterparty and settled in cash. The filing lists an approximate aggregate market value of $1,758,145.35 for the shares and notes that 35,730,843 shares of the issuer’s common stock are outstanding, as context for the planned disposition.

First Tracks Biotherapeutics, Inc. (symbol: TRAX) is the issuer of record for a Form 4 filing submitted to the SEC.

First Tracks Biotherapeutics, Inc. (symbol: TRAX) is the issuer of record for a Form 4 filing submitted to the SEC.